Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cara Therapeutics (CARA)

Cara Therapeutics (CARA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 781,404
  • Shares Outstanding, K 50,090
  • Annual Sales, $ 135,080 K
  • Annual Income, $ 8,410 K
  • 60-Month Beta 1.08
  • Price/Sales 5.68
  • Price/Cash Flow 79.28
  • Price/Book 3.75
Trade CARA with:

Options Overview Details

View History
  • Implied Volatility 73.32%
  • Historical Volatility 47.65%
  • IV Percentile 27%
  • IV Rank 13.20%
  • IV High 201.67% on 08/16/21
  • IV Low 53.81% on 06/16/21
  • Put/Call Vol Ratio 0.30
  • Today's Volume 767
  • Volume Avg (30-Day) 2,772
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 12,092
  • Open Int (30-Day) 31,692

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.36
  • Number of Estimates 5
  • High Estimate 0.00
  • Low Estimate -0.73
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -2.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.40 +16.42%
on 08/26/21
18.25 -14.52%
on 08/24/21
+1.90 (+13.87%)
since 08/20/21
3-Month
11.22 +39.04%
on 08/04/21
18.25 -14.52%
on 08/24/21
+1.26 (+8.79%)
since 06/21/21
52-Week
11.22 +39.04%
on 08/04/21
29.65 -47.38%
on 04/09/21
+1.45 (+10.25%)
since 09/21/20

Most Recent Stories

More News
Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update

Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.

REGN : 646.95 (+0.95%)
PFE : 43.92 (-0.63%)
MRNA : 434.04 (+2.53%)
TBPH : 7.10 (+3.20%)
CARA : 15.60 (+1.89%)
BNTX : 341.35 (+0.69%)
CARA Drug Wins FDA Nod for Pruritus Associated With CKD

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

REGN : 646.95 (+0.95%)
HZNP : 109.76 (+1.61%)
RGEN : 314.18 (+2.66%)
CARA : 15.60 (+1.89%)
Pre-Market Brief: U.S. Stocks Set to Open at Record Highs

Morning Markets Sep S&P 500 futures this morning are up +0.07% and posted a new all-time nearest-futures high in overnight trade. Stock indexes gave up most of their gains as European stocks turned lower....

PANW : 473.03 (-0.29%)
BBY : 106.89 (+0.21%)
CARA : 15.60 (+1.89%)
PDD : 95.10 (+0.98%)
BABA : 150.18 (-0.86%)
JD : 73.50 (-0.88%)
TCEHY : 58.1000 (+2.51%)
CRWD : 254.11 (-1.34%)
WYNN : 78.77 (-4.07%)
LVS : 35.59 (-5.57%)
MLCO : 10.04 (-3.00%)
VSCO : 61.80 (+2.44%)
AAP : 205.66 (+0.96%)
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA(TM) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News:

GNHAF : 127.0000 (-11.31%)
CARA : 15.60 (+1.89%)
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

CARA : 15.60 (+1.89%)
Cara Therapeutics (CARA) Reports Q2 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -10.91% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CARA : 15.60 (+1.89%)
Cara: Q2 Earnings Snapshot

STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Monday reported a loss of $30.7 million in its second quarter.

CARA : 15.60 (+1.89%)
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CARA : 15.60 (+1.89%)
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics

/PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...

SWKH : 18.33 (+1.83%)
CARA : 15.60 (+1.89%)
Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels

PALM BEACH,  Fla., /PRNewswire/ --  The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing...

RTSL : 0.2500 (unch)
JAZZ : 129.10 (+0.36%)
NTEC : 9.63 (-12.48%)
CARA : 15.60 (+1.89%)
ARNA : 60.64 (+1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

3rd Resistance Point 16.29
2nd Resistance Point 16.02
1st Resistance Point 15.81
Last Price 15.60
1st Support Level 15.33
2nd Support Level 15.06
3rd Support Level 14.85

See More

52-Week High 29.65
Fibonacci 61.8% 22.61
Fibonacci 50% 20.43
Fibonacci 38.2% 18.26
Last Price 15.60
52-Week Low 11.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar